The abstract is read at the publisher; the summary is JClub's.
Two full doses of Sabin IPV in a routine bOPV sequential schedule achieved type 2 seroconversion in 99% of infants at 10 months, non-inferior to Salk IPV.
- Why it matters: Routine bOPV-IPV sequential schedules are used in infancy, but immunogenicity and safety evidence for Sabin IPV in this setting is limited.
- What they did: In a single-centre, double-blind, randomised non-inferiority trial in Bhaktapur, Nepal, infants received bOPV at 6, 10, and 14 weeks plus two intramuscular IPV doses at 14 weeks and 9 months, comparing Sabin IPV versus Salk IPV.
- The result: Type 2 seroconversion at age 10 months occurred in 210/212 (99% [95% CI 97–100]) with Sabin IPV versus 214/215 (100% [97–100]) with Salk IPV (risk difference -0·5% [-2·1 to 1·1]); fever was common and no serious adverse events were causally related to IPV.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.